Mark Ashwell

In the United States, there are 10 individuals named Mark Ashwell spread across 13 states, with the largest populations residing in California, Connecticut, Florida.

Public information about Mark Ashwell

Resumes

Mark Ashwell

Managing Partner At Mla Consultancy Services

Position:

Managing Partner at MLA Consultancy Services

Location:

Hemel Hempstead, United Kingdom

Industry:

Defense & Space

Work:

MLA Consultancy Services - High Wycombe since Feb 2012
Managing Partner DigitalGlobe - Denver Colorado Sep 2009 - Feb 2012
VP International Business Development Royal Air Force - Defence Intelligence MOD London Apr 2007 - Sep 2009
Director Intelligence Capability Strategy &Policy UK Ministry of Defence - Defence Intelligence London Mar 2005 - Apr 2007
Director Joint Narcotics Analysis Centre UK Ministry of Defence - Defence Intelligence London May 2004 - Mar 2005
Director International Terrorism and Organised Crime Group Royal Air Force - Strike Command High Wycombe Sep 2001 - Apr 2004
Director Air Battle Management Branch

Education:

London University 1977 - 1980
Bachelor of Science (BSc), Zoology/Animal Biology

Honor & Awards:

MBE

Mark Ashwell

Managing Director

Location:

Houston, TX

Industry:

Oil & Energy

Work:

Oes Oilfield Services Group
Global Account Director Fabric Architecture Limited Mar 1994 - Dec 1999
Project Manager Jumeirah Group / Jumeirah Hotels & Resorts May 1991 - Jan 1994
Director of Leisure Sales May 1991 - Jan 1994
Managing Director

Education:

Farnborough College of Technology 1987 - 1991
Bachelors, Bachelor of Arts, Business Management Yateley School 1984 - 1987
Northcliffe School - Southampton 1979 - 1983

Skills:

Offshore, Inspection, Offshore Drilling, Drilling, Petroleum, Oil/Gas, Onshore, Subsea Engineering, Oilfield, Directional Drilling, Energy, Upstream, Energy Industry, Safety Management Systems, Gas, Qhse, Offshore Operations, Commissioning, Completion

Mark Ashwell

Consultant

Location:

Woburn, MA

Industry:

Pharmaceuticals

Work:

Nimbus Therapeutics 2016 - Feb 2020
Svp, Head of Chemistry Ashwell Consulting Group 2016 - Feb 2020
Consultant Arqule 2005 - Dec 2013
Vice President and Head of Chemistry Arqule 2001 - 2004
Director, Discovery Chemistry Wyeth-Ayerst Research 1995 - 2001
Research Leader Pfizer 1991 - 1995
Medicinal Chemist University of Illinois at Chicago 1989 - 1990
Postdoctoral Research Fellow Newcastle University 1986 - 1988
Postdoctoral Research Fellow International Agency For Research on Cancer / World Health Organization 1987 - 1988
Who Consultant

Education:

University of Birmingham 1983 - 1986
Doctorates, Doctor of Philosophy, Philosophy, Organic Chemistry

Skills:

Drug Discovery, Medicinal Chemistry, Drug Development, Drug Design, Organic Chemistry, Biotechnology, Oncology, Biochemistry, Chemistry, Adme, Organic Synthesis, Lead Change, Clinical Development, High Throughput Screening, Analytical Chemistry, Parallel Synthesis, Lc Ms, Assay Development, Patents, Cheminformatics, Protein Kinases, Project Management, Liquid Chromatography Mass Spectrometry, Patent Law, Technology, Cns Disorders, Inflammation

Background search with BeenVerified

Background Search for Mark Ashwell

Phone Address Email Family Social Criminal Property Bankruptcy Residence

Data provided by Veripages

Publications

Us Patents

Substituted Dihydrophenanthridinesulfonamides

US Patent:

6894061, May 17, 2005

Filed:

Nov 20, 2003

Appl. No.:

10/718461

Inventors:

Albert John Molinari - Pottstown PA, US
Mark Antony Ashwell - Carlisle MA, US
Brian Hugh Ridgway - Belmont CA, US
Amedeo Arturo Failli - Princeton Junction NJ, US
William Jay Moore - Collegeville PA, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K031/473
C07D221/12

US Classification:

514298, 546108, 546109, 546110, 544324, 514269

Abstract:

This invention provides a compound of formulae (I) or (II) having the structure or a pharmaceutically acceptable salt thereof which are useful for the treatment of the inflammatory component of diseases and are particularly useful in treating atherosclerosis, myocardial infarction, congestive heart failure, inflammatory bowel disease, arthritis, type II diabetes, and autoimmune diseases such as multiple sclerosis and rheumatiod arthritis.

Substituted 4-(Indazol-3-Yl)Phenols

US Patent:

7241791, Jul 10, 2007

Filed:

Sep 24, 2003

Appl. No.:

10/670646

Inventors:

Robert J. Steffan - Langhorne PA, US
Edward M. Matelan - Royersford PA, US
Mark A. Ashwell - Carlisle MA, US
William R. Solvibile - East Windsor NJ, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 31/416
C07D 231/56

US Classification:

514403, 514406, 5483611

Abstract:

This invention provides compound of formulae I or II having the structure.

Heterocyclic -3 Adrenergic Receptor Agonists

US Patent:

6451814, Sep 17, 2002

Filed:

Jul 12, 2001

Appl. No.:

09/903841

Inventors:

Mark Anthony Ashwell - Plainsboro NJ
William Ronald Solvibile - East Windsor NJ
Dominick Anthony Quagliato - Bridgewater NJ
Albert John Molinari - Princeton NJ

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 3147

US Classification:

514313, 514312, 514317, 514324, 546156, 546192, 546195

Abstract:

This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

Processes For Preparing 6-Alkyl-5-Arylsulfonyl-Dihydrophenanthridines

US Patent:

7378427, May 27, 2008

Filed:

Jun 17, 2005

Appl. No.:

11/155851

Inventors:

Brian Hugh Ridgway - Belmont CA, US
William Jay Moore - Collegeville PA, US
Mark Anthony Ashwell - Carlisle MA, US
William Ronald Solvibile - East Windsor NJ, US
Amy Tsai-Ting Lee - Los Altos CA, US
Molly Elizabeth Hoke - Hightstown NJ, US
Madelene Antane - West Windsor NJ, US
Amedeo A. Failli - Princeton Junction NJ, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K 31/44
C07D 221/12

US Classification:

514298, 546108

Abstract:

Synthetic methods are provided for production of compounds of the formula:.

Raf Inhibitors And Their Uses

US Patent:

7501430, Mar 10, 2009

Filed:

Apr 16, 2007

Appl. No.:

11/785163

Inventors:

Jean-Marc Lapierre - Pelham NH, US
Nivedita D. Namdev - Westford MA, US
Mark A. Ashwell - Carlisle MA, US
Dennis S. France - Carlisle MA, US
Hui Wu - Malden MA, US
Patrick M. Hutchins - Denver CO, US
Manish Tandon - Framingham MA, US
Yanbin Liu - Acton MA, US
Jeff S. Link - Londonderry NH, US
Syed M. Ali - North Andover MA, US
Chris J. Brassard - Somerville MA, US
Robb B. Nicewonger - Tyngsboro MA, US
Anton Filikov - Stoneham MA, US
Rebecca J. Carazza - Winchester MA, US

Assignee:

ArQule, Inc. - Woburn MA

International Classification:

C07D 498/04
C07D 513/04
A61K 31/429
A61K 31/4188

US Classification:

514275, 544333

Abstract:

The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAF. The compounds are useful for the treatment of cell proliferative disorders such as cancer.

Substituted 2-(S)-Hydroxy-3-(Piperidin-4-Yl-Methylamino)-Propyl Ethers And Substituted 2-Aryl-2-(R)-Hydroxy-1-(Piperidin-4-Yl-Methyl)-Ethylamine -3 Adrenergic Receptor Agonists

US Patent:

6506901, Jan 14, 2003

Filed:

Jul 12, 2001

Appl. No.:

09/903738

Inventors:

Robert John Steffan - Langhorne PA
Mark Anthony Ashwell - Plainsboro NJ
Jeffrey Claude Pelletier - Lafayette Hill PA
William Ronald Solvibile - East Windsor NJ
Edward Martin Matelan - Yardley PA

Assignee:

Wyeth - Madison NJ

International Classification:

C07D21196

US Classification:

546192, 514327

Abstract:

This invention provides compounds of Formula I having the structure wherein A, B, Z, R and R are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

Compositions And Methods For Treatment Of Cancer

US Patent:

7713969, May 11, 2010

Filed:

Feb 9, 2006

Appl. No.:

11/350335

Inventors:

Chiang J. Li - West Roxbury MA, US
Mark A. Ashwell - Carlisle MA, US
Jason Hill - Auburndale MA, US
Magdi M. Moussa - Malden MA, US
Neru Munshi - Burlington MA, US

Assignee:

ArQule, Inc. - Woburn MA

International Classification:

A61P 35/00
A61K 31/473
A61K 31/551
A61K 31/661
C07D 471/06
C07D 487/06
C07F 9/12

US Classification:

5142332, 514294, 544126, 546 94

Abstract:

The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

Pharmaceutical Compositions Of Β-Lapachone And Β-Lapachone Analogs With Improved Tumor Targeting Potential

US Patent:

7812051, Oct 12, 2010

Filed:

Aug 11, 2005

Appl. No.:

11/201097

Inventors:

Mark A. Ashwell - Carlisle MA, US
Chiang J. Li - West Roxbury MA, US
Manish Tandon - Framingham MA, US
Yanbin Liu - Acton MA, US
Jean-Marc LaPierre - Pelham NH, US
Zhiwei Jiang - Stow MA, US

Assignee:

ArQule, Inc. - Woburn MA

International Classification:

A61K 31/352
C07D 311/92

US Classification:

514454, 514455, 424423, 549389

Abstract:

The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified β-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as β-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues.

Videos & Images

Youtube

Making History.f4V

Duration:

3m 50s

Category:

News & Politics

Description:

Mr Speaker and the Peachettes campaign to get Mark Ashwell, the Independent Candidate for Wokingham and West Berkshire, elected as a Member of Parliament in the 2010 general election. The independent view is becoming more and more popular within local communities because of the unproductive and cons...

Interview With Mark Ashwell.wmv

Duration:

6m 52s

Channel:

PlanetChurcher

Magical Pass V6.F4V

Duration:

4m 24s

Category:

News & Politics

Description:

Nicholas Hoult asks Mark Ashwell about his approach to politics and why Mark is standing for election for the Member of Parliament for Wokingham in the 2010 general Elections,

Mark Ashwell Hitting A Putter Out Of The Tee Box

Duration:

Channel:

Jay Mendoza

Description:

This video was uploaded from an Android phone.

Emotional Ashwell Prince Highlights Racism In South Africa Cricket

Duration:

5m 32s

Channel:

Cricbuzz

Description:

'Colour doesn't matter in cricket,' says former cricketer #AshwellPrince, as he talks about prevalent racism in South Africa during a...

In The Running.f4V

Duration:

1m 6s

Category:

News & Politics

Description:

Mark Ashwell competes in the Wokingham Half Marthon - running for Wokingham and for the 2010 General Election as an Independent MP for Wokingham. Working hard to improve his position in

The Dark Side Of Ashwagandha

Duration:

5m 14s

Channel:

Mark Bell's Power Project

Description:

Lucas Aoun @BoostYourBiolog... is Australia's leading biohacker, with over 7 years of experience researching and experimenting....

Mark Templeton & Pocket Change - When The Sun Of My Life Goes Down

Duration:

3m 11s

Channel:

Lovin' Bluegrass by Carol McDuffie

Description:

Mark Tempelton, Banjo Glenn Ashwell, Guitar Ralph Clay, Bass Ernie Power, Dobro.

FAQ: Learn more about Mark Ashwell

What are the previous addresses of Mark Ashwell?

Previous addresses associated with Mark Ashwell include: 8061 Hidden Cir, Chanhassen, MN 55317; 8 Heald Rd, Carlisle, MA 01741; 147 Finney Rd, Glenmoore, PA 19343; 2601 Sinclair Ave, Concord, CA 94519; 1630 Clayton Rd, Concord, CA 94520. Remember that this information might not be complete or up-to-date.

Where does Mark Ashwell live?

Saint Paul, MN is the place where Mark Ashwell currently lives.

How old is Mark Ashwell?

Mark Ashwell is 48 years old.

What is Mark Ashwell date of birth?

Mark Ashwell was born on 1975.

What is Mark Ashwell's telephone number?

Mark Ashwell's known telephone numbers are: 978-318-3944, 610-458-8084, 320-587-2799. However, these numbers are subject to change and privacy restrictions.

Who is Mark Ashwell related to?

Known relatives of Mark Ashwell are: Teddy Helton, John Kinder, Madisyn Hofer, Matthew Hofer, Clark Hodell, Kristen Ashwell, Jaeme Ruffert. This information is based on available public records.

What is Mark Ashwell's current residential address?

Mark Ashwell's current known residential address is: 4753 W Alabama St, Houston, TX 77027. Please note this is subject to privacy laws and may not be current.

What are the previous addresses of Mark Ashwell?

Name Variants	Marc Ashwell	Marcus Ashwell	Markus Ashwell
Ages	48 to 66
Phones	978-318-3944	610-458-8084	320-587-2799
Addresses	4753 W Alabama St, Houston, TX 77027	8061 Hidden Cir, Chanhassen, MN 55317	8 Heald Rd, Carlisle, MA 01741
Business records	Managing Partner / MLA Consultancy Services	Technical Support Manager, Molecular Diagnostics / Beckman Coulter	Svp, Head of Chemistry / Nimbus Therapeutics

Mark Ashwell

What do we know about Mark Ashwell

Public information about Mark Ashwell

Resumes

Resumes

Mark Ashwell

Mark Ashwell

Managing Partner At Mla Consultancy Services

Mark Ashwell

Mark Ashwell

Managing Director

Mark Ashwell

Consultant

Publications

Us Patents

Substituted Dihydrophenanthridinesulfonamides

Substituted 4-(Indazol-3-Yl)Phenols

Heterocyclic -3 Adrenergic Receptor Agonists

Processes For Preparing 6-Alkyl-5-Arylsulfonyl-Dihydrophenanthridines

Raf Inhibitors And Their Uses

Substituted 2-(S)-Hydroxy-3-(Piperidin-4-Yl-Methylamino)-Propyl Ethers And Substituted 2-Aryl-2-(R)-Hydroxy-1-(Piperidin-4-Yl-Methyl)-Ethylamine -3 Adrenergic Receptor Agonists

Compositions And Methods For Treatment Of Cancer

Pharmaceutical Compositions Of Β-Lapachone And Β-Lapachone Analogs With Improved Tumor Targeting Potential

FAQ: Learn more about Mark Ashwell

Possible Relatives